A Phase 3 interventional study of Vortioxetine and Placebo in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-03.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Generalized Anxiety Disorder with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Generalized Anxiety Disorder · Russian Federation.
Among the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation, this one is the 8th largest by enrollment, is one of 4 that started in 2008, is one of 7 in phase 3, and was the 7th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →None of the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation is open now. The open studies under Generalized Anxiety Disorder, anywhere →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 405 across the 10 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 6 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 5 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Generalized Anxiety Disorder with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat anxiety in adults who have general anxiety disorder (GAD). This study looked at GAD relief in people who took vortioxetine.
The study enrolled 301 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):
All participants were asked to take one capsule at the same time each day throughout the study.
This multi-center trial was conducted in Europe. The overall time to participate in this study was up to 13 weeks. Participants made 7 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has 1 or more of the following:
Is required to take excluded medications or it is anticipated that the participant will require treatment with at least 1 of the disallowed concomitant medications during the study including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
Drug: Placebo
Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
Drug: Vortioxetine
Encapsulated vortioxetine immediate-release tablets.
Also known as: Lu AA21004, Brintellix®
Vortioxetine placebo-matching capsules
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8
The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Clinical Global Impression Scale-Global Improvement at Week 8
The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Percentage of Responders in HAM-A Total Score at Week 8
Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Baseline and Week 8
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Week 8
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 2, 4 and 6.
Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Other Weeks Assessed
The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1 and 4
Clinical Global Impression Scale-Global Improvement at Other Weeks Assessed
The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 2, 4 and 6
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Other Weeks Assessed
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 2 and 4
Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Baseline and Weeks 1, 2, 4 and 6
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 2, 4 and 6
Percentage of Participants in HAM-A Remission at Each Week Assessed
Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Weeks 1, 2, 4, 6 and 8
Change From Baseline in Clinical Global Impression Scale-Severity of Illness at Each Week Assessed
The Clinical Global Impression-Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 2, 4, 6 and 8
Change From Baseline in the Hospital Anxiety and Depression (HAD) Depression Subscale at Each Week Assessed
The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 1, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Other Weeks Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2 and 4
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Functioning Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Physical Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Bodily Pain Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Vitality Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Role-Emotional Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Mental Health Subscore at Each Week Assessed
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
Time frame: Baseline to Weeks 2, 4 and 8
Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Time frame: Baseline and Week 8
Participants took part in the study at 47 investigative sites in Europe from 23 September 2008 to 07 July 2009.
| Milestone | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Started | 151 | 150 |
| Treated | 150 | 150 |
| Completed | 126 | 128 |
| Not completed | 25 | 22 |
| Withdrew: Adverse event | 6 | 9 |
| Withdrew: Lack of efficacy | 7 | 3 |
| Withdrew: Noncompliance | 0 | 1 |
| Withdrew: Protocol deviations | 0 | 2 |
| Withdrew: Voluntary withdrawal | 9 | 6 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Other | 1 | 0 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 | -10.49 ± 0.697 | -14.30 ± 0.695 |
The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Change From Baseline in the Hospital Anxiety and Depression (HAD) Anxiety Subscale at Week 8 | -4.20 ± 0.396 | -6.49 ± 0.393 |
The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Clinical Global Impression Scale-Global Improvement at Week 8 | 2.66 ± 0.098 | 2.19 ± 0.098 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8 | -6.14 ± 0.631 | -8.10 ± 0.656 |
Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Percentage of Responders in HAM-A Total Score at Week 8 | 39.9 | 61.7 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25 | -10.44 ± 0.895 | -15.55 ± 0.904 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Social Functioning Subscore at Week 8 | 18.02 ± 1.991 | 26.80 ± 1.974 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | -2.46 ± 0.272 | -2.50 ± 0.270 |
| Week 2 (n=147, 144) | -5.05 ± 0.407 | -6.21 ± 0.408 |
| Week 4 (n=136, 137) | -7.43 ± 0.539 | -9.62 ± 0.538 |
| Week 6 (n=128, 129) | -9.17 ± 0.609 | -11.93 ± 0.608 |
The Hospital Anxiety and Depression (HAD) Anxiety sub-scale consists of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). The anxiety subscale determines a state of generalized anxiety including anxious mood, restlessness, anxious thoughts and panic attacks. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | -1.42 ± 0.226 | -1.14 ± 0.223 |
| Week 4 (n=140, 140) | -3.13 ± 0.298 | -4.07 ± 0.296 |
The Clinical Global Impression-Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | 3.58 ± 0.053 | 3.67 ± 0.053 |
| Week 2 (n=147, 144) | 3.31 ± 0.070 | 3.10 ± 0.070 |
| Week 4 (n=136, 137) | 2.99 ± 0.080 | 2.66 ± 0.080 |
| Week 6 (n=128, 129) | 2.74 ± 0.086 | 2.43 ± 0.086 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=121, 117) | -1.32 ± 0.314 | -1.12 ± 0.329 |
| Week 2 (n=122, 114) | -2.93 ± 0.440 | -3.04 ± 0.459 |
| Week 4 (n=112, 107) | -4.35 ± 0.546 | -5.13 ± 0.566 |
Response was defined as participants with a ≥ 50% decrease from Baseline in the Hamilton Anxiety Scale (HAM-A) total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | 2.7 | 2.0 |
| Week 2 (n=148, 149) | 12.2 | 12.1 |
| Week 4 (n=148, 149) | 20.3 | 28.9 |
| Week 6 (n=148, 149) | 29.7 | 43.6 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=100, 95) | -2.64 ± 0.332 | -2.62 ± 0.341 |
| Week 2 (n=99, 92) | -4.89 ± 0.507 | -6.43 ± 0.522 |
| Week 4 (n=89, 89) | -7.33 ± 0.694 | -10.08 ± 0.702 |
| Week 6 (n=83, 83) | -9.02 ± 0.763 | -12.90 ± 0.771 |
Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | 0 | 0 |
| Week 2 (n=148, 149) | 2.7 | 2.7 |
| Week 4 (n=148, 149) | 6.8 | 8.7 |
| Week 6 (n=148, 149) | 12.2 | 16.8 |
| Week 8 (n=148, 149) | 17.6 | 30.2 |
The Clinical Global Impression-Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | -0.23 ± 0.039 | -0.19 ± 0.039 |
| Week 2 (n=147, 144) | -0.53 ± 0.060 | -0.60 ± 0.060 |
| Week 4 (n=136, 137) | -0.87 ± 0.071 | -1.04 ± 0.071 |
| Week 6 (n=128, 129) | -1.09 ± 0.080 | -1.40 ± 0.080 |
| Week 8 (n=126, 128) | -1.26 ± 0.096 | -1.78 ± 0.095 |
The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 1 (n=146, 148) | -0.18 ± 0.178 | -0.28 ± 0.176 |
| Week 4 (n=140, 140) | -1.08 ± 0.245 | -1.62 ± 0.245 |
| Week 8 (n=128, 129) | -1.50 ± 0.297 | -3.18 ± 0.295 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 8.50 ± 1.536 | 8.83 ± 1.519 |
| Week 4 (n=136, 137) | 11.41 ± 1.773 | 18.45 ± 1.758 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The physical functioning subscale assesses limitations in physical activities because of health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 2.54 ± 1.160 | 3.39 ± 1.146 |
| Week 4 (n=136, 137) | 2.15 ± 1.149 | 8.34 ± 1.137 |
| Week 8 (n=128, 129) | 4.48 ± 1.271 | 10.69 ± 1.258 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-physical subscale assesses limitations in usual role activities because of physical health problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 4.72 ± 1.488 | 5.99 ± 1.474 |
| Week 4 (n=136, 137) | 6.89 ± 1.592 | 11.89 ± 1.578 |
| Week 8 (n=128, 129) | 8.96 ± 1.897 | 18.39 ± 1.880 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The bodily pain sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 6.49 ± 1.702 | 7.40 ± 1.681 |
| Week 4 (n=136, 137) | 6.81 ± 1.875 | 10.62 ± 1.856 |
| Week 8 (n=128, 129) | 10.90 ± 1.903 | 15.38 ± 1.883 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The general health sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 4.54 ± 0.992 | 6.04 ± 0.979 |
| Week 4 (n=136, 137) | 8.45 ± 1.292 | 10.36 ± 1.280 |
| Week 8 (n=128, 129) | 9.76 ± 1.409 | 16.30 ± 1.396 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The vitality sub-score assesses energy and fatigue, and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 5.44 ± 1.275 | 8.11 ± 1.261 |
| Week 4 (n=136, 137) | 8.36 ± 1.500 | 13.38 ± 1.486 |
| Week 8 (n= 128, 129) | 12.56 ± 1.686 | 22.53 ± 1.671 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. The sub-score scale ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 7.27 ± 1.480 | 9.62 ± 1.463 |
| Week 4 (n=136, 137) | 13.41 ± 1.871 | 19.04 ± 1.856 |
| Week 8 (n=128, 129) | 18.96 ± 2.138 | 28.13 ± 2.121 |
The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The mental health sub-score assesses general mental health (psychological distress and well-being) and ranges from 0 (best) - 100 (worst). LS means were from a MMRM with Baseline-by-week, center, week and week-by-treatment as factors in the analysis.
| scores on a scale | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Week 2 (n=147, 149) | 5.58 ± 1.166 | 8.90 ± 1.152 |
| Week 4 (n=136, 137) | 9.79 ± 1.432 | 14.73 ± 1.421 |
| Week 8 (n=128, 129) | 13.51 ± 1.693 | 21.75 ± 1.681 |
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
| participants | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Baseline: Any resource use | 79 | 84 |
| Baseline: Any hospitalization-related services | 7 | 3 |
| Baseline: Hospitalization related to anxiety | 4 | 2 |
| Baseline: Any sick leave | 7 | 7 |
| Baseline: Sick leave related to anxiety | 4 | 4 |
| Week 8: Any resource use | 14 | 25 |
| Week 8: Any hospitalization-related service | 0 | 1 |
| Week 8: Hospitalization related to anxiety | 0 | 0 |
| Week 8: Any sick leave | 2 | 4 |
| Week 8: Sick leave related to anxiety | 2 | 3 |
Collected over Safety was assessed during the 8-week treatment period and a 4-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/150 (0.7%) | 36/150 (24%) |
| Vortioxetine 5 mg | — | 0/150 (0%) | 48/150 (32%) |
| Event | Placebo | Vortioxetine 5 mg |
|---|---|---|
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/150 | 0/150 |
| Event | Placebo | Vortioxetine 5 mg |
|---|---|---|
| NauseaGastrointestinal disorders | 9/150 | 18/150 |
| HeadacheNervous system disorders | 13/150 | 12/150 |
| DizzinessNervous system disorders | 4/150 | 9/150 |
| SomnolenceNervous system disorders | 2/150 | 6/150 |
| Dry mouthGastrointestinal disorders | 4/150 | 5/150 |
| VomitingGastrointestinal disorders | 5/150 | 2/150 |
| NasopharyngitisInfections and infestations | 1/150 | 5/150 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/150 | 5/150 |
| DiarrhoeaGastrointestinal disorders | 4/150 | 3/150 |
| FatigueGeneral disorders | 4/150 | 1/150 |
| Age, Continuous(years) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Mean | 45.3 ± 13.49 | 45.0 ± 14.07 | 45.1 ± 13.76 |
| Age, Customized(participants) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| ≤55 years | 112 | 111 | 223 |
| >55 years | 39 | 39 | 78 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Female | 93 | 103 | 196 |
| Male | 58 | 47 | 105 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Caucasian (White, including Hispanic) | 151 | 150 | 301 |
| Black | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian/ Other Pacific Islander | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Hispanic/Latino | 8 | 5 | 13 |
| Non-Hispanic/Non-Latino | 143 | 145 | 288 |
| Region of Enrollment(participants) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Estonia | 7 | 3 | 10 |
| Germany | 34 | 37 | 71 |
| Latvia | 7 | 5 | 12 |
| Lithuania | 8 | 11 | 19 |
| Poland | 28 | 31 | 59 |
| Romania | 5 | 3 | 8 |
| Russia | 48 | 49 | 97 |
| Ukraine | 14 | 11 | 25 |
| Weight(kg) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Mean | 75.76 ± 16.370 | 72.97 ± 14.981 | 74.37 ± 15.729 |
| Height(cm) | Placebo | Vortioxetine 5 mg | Total |
|---|---|---|---|
| Mean | 169.56 ± 9.457 | 168.21 ± 8.653 | 168.89 ± 9.075 |
8 further baseline measures are reported on the registry.
The record gives a start of Sep 2008, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine
Generalized Anxiety Disorder →